Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
135 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pandemic Influenza - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Pandemic Influenza - Pipeline Review, H1 2015', provides an overview of the Pandemic Influenza's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Pandemic Influenza Overview 8 Therapeutics Development 9 Pipeline Products for Pandemic Influenza - Overview 9 Pipeline Products for Pandemic Influenza - Comparative Analysis 10 Pandemic Influenza - Therapeutics under Development by Companies 11 Pandemic Influenza - Therapeutics under Investigation by Universities/Institutes 15 Pandemic Influenza - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Pandemic Influenza - Products under Development by Companies 19 Pandemic Influenza - Products under Investigation by Universities/Institutes 22 Pandemic Influenza - Companies Involved in Therapeutics Development 23 AIMM Therapeutics B.V. 23 AltraVax Inc. 24 AmVac AG 25 Big DNA Ltd. 26 BioDiem Ltd 27 Celltrion, Inc. 28 Cilian AG 29 Codagenix, Inc. 30 ContraFect Corporation 31 Emergent BioSolutions Inc. 32 GlaxoSmithKline plc 33 Hemispherx Biopharma, Inc. 34 Immunovaccine, Inc. 35 Johnson & Johnson 36 Medicago Inc. 37 NanoBio Corporation 38 Novartis AG 39 Novavax, Inc. 40 OPKO Health, Inc. 41 PDS Biotechnology Corporation 42 PeptiVir, Inc. 43 Protein Sciences Corporation 44 Sinovac Biotech Ltd. 45 Sirnaomics, Inc. 46 TaiGen Biotechnology Co., Ltd. 47 TechnoVax, Inc. 48 Theraclone Sciences, Inc. 49 TSRL, Inc. 50 UMN Pharma Inc. 51 VaxInnate Corporation 52 Pandemic Influenza - Therapeutics Assessment 53 Assessment by Monotherapy Products 53 Assessment by Combination Products 54 Assessment by Target 55 Assessment by Mechanism of Action 57 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 A-06 - Drug Profile 63 Alferon LDO - Drug Profile 64 AMV-411 - Drug Profile 65 BDNA-002 - Drug Profile 66 Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza - Drug Profile 67 CF-404 - Drug Profile 68 CiFlu - Drug Profile 69 CTP-25 - Drug Profile 71 CTP-27 - Drug Profile 72 flu pandemic (H5N1) vaccine - Drug Profile 73 IKT-041 - Drug Profile 74 influenza (H5) vaccine - Drug Profile 75 influenza [H7N9] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 76 influenza [strain H5N1] (monovalent) vaccine - Drug Profile 77 influenza [strain H7N9] (monovalent) vaccine - Drug Profile 78 influenza vaccine - Drug Profile 80 influenza vaccine - Drug Profile 81 influenza vaccine - Drug Profile 82 influenza vaccine - Drug Profile 83 Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza - Drug Profile 84 Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile 85 Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 86 MVAH-5HA - Drug Profile 87 pandemic infleunza vaccine - Drug Profile 88 pandemic influenza [H5N1] vaccine - Drug Profile 89 pandemic influenza [H7N9] (monovalent) vaccine - Drug Profile 90 pandemic influenza vaccine - Drug Profile 91 pandemic influenza vaccine - Drug Profile 92 pandemic influenza vaccine - Drug Profile 93 pandemic influenza vaccine - Drug Profile 94 pandemic influenza vaccine - Drug Profile 95 pandemic influenza vaccine - Drug Profile 96 pandemic influenza vaccine [H5N1] - Drug Profile 97 PDS-0102 - Drug Profile 98 PVI-1000 - Drug Profile 99 Small Molecules for Influenza - Drug Profile 100 Small Molecules for Influenza - Drug Profile 101 Small Molecules for Pandemic Influenza - Drug Profile 102 STP-702 - Drug Profile 103 TCN-032 - Drug Profile 104 TSR-026 - Drug Profile 106 TSR-462 - Drug Profile 107 TVX-002 - Drug Profile 108 UMN-0501 - Drug Profile 109 UMN-0901 - Drug Profile 111 VAX-161 - Drug Profile 112 VAX-16101C - Drug Profile 113 VX-787 - Drug Profile 114 Pandemic Influenza - Recent Pipeline Updates 115 Pandemic Influenza - Dormant Projects 124 Pandemic Influenza - Discontinued Products 126 Pandemic Influenza - Product Development Milestones 127 Featured News & Press Releases 127 Appendix 131 Methodology 131 Coverage 131 Secondary Research 131 Primary Research 131 Expert Panel Validation 131 Contact Us 131 Disclaimer 132
List of Tables Number of Products under Development for Pandemic Influenza, H1 2015 12 Number of Products under Development for Pandemic Influenza - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Development by Companies, H1 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Comparative Analysis by Unknown Stage Development, H1 2015 21 Products under Development by Companies, H1 2015 22 Products under Development by Companies, H1 2015 (Contd..1) 23 Products under Development by Companies, H1 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2015 25 Pandemic Influenza - Pipeline by AIMM Therapeutics B.V., H1 2015 26 Pandemic Influenza - Pipeline by AltraVax Inc., H1 2015 27 Pandemic Influenza - Pipeline by AmVac AG, H1 2015 28 Pandemic Influenza - Pipeline by Big DNA Ltd., H1 2015 29 Pandemic Influenza - Pipeline by BioDiem Ltd, H1 2015 30 Pandemic Influenza - Pipeline by Celltrion, Inc., H1 2015 31 Pandemic Influenza - Pipeline by Cilian AG, H1 2015 32 Pandemic Influenza - Pipeline by Codagenix, Inc., H1 2015 33 Pandemic Influenza - Pipeline by ContraFect Corporation, H1 2015 34 Pandemic Influenza - Pipeline by Emergent BioSolutions Inc., H1 2015 35 Pandemic Influenza - Pipeline by GlaxoSmithKline plc, H1 2015 36 Pandemic Influenza - Pipeline by Hemispherx Biopharma, Inc., H1 2015 37 Pandemic Influenza - Pipeline by Immunovaccine, Inc., H1 2015 38 Pandemic Influenza - Pipeline by Johnson & Johnson, H1 2015 39 Pandemic Influenza - Pipeline by Medicago Inc., H1 2015 40 Pandemic Influenza - Pipeline by NanoBio Corporation, H1 2015 41 Pandemic Influenza - Pipeline by Novartis AG, H1 2015 42 Pandemic Influenza - Pipeline by Novavax, Inc., H1 2015 43 Pandemic Influenza - Pipeline by OPKO Health, Inc., H1 2015 44 Pandemic Influenza - Pipeline by PDS Biotechnology Corporation, H1 2015 45 Pandemic Influenza - Pipeline by PeptiVir, Inc., H1 2015 46 Pandemic Influenza - Pipeline by Protein Sciences Corporation, H1 2015 47 Pandemic Influenza - Pipeline by Sinovac Biotech Ltd., H1 2015 48 Pandemic Influenza - Pipeline by Sirnaomics, Inc., H1 2015 49 Pandemic Influenza - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 50 Pandemic Influenza - Pipeline by TechnoVax, Inc., H1 2015 51 Pandemic Influenza - Pipeline by Theraclone Sciences, Inc., H1 2015 52 Pandemic Influenza - Pipeline by TSRL, Inc., H1 2015 53 Pandemic Influenza - Pipeline by UMN Pharma Inc., H1 2015 54 Pandemic Influenza - Pipeline by VaxInnate Corporation, H1 2015 55 Assessment by Monotherapy Products, H1 2015 56 Assessment by Combination Products, H1 2015 57 Number of Products by Stage and Target, H1 2015 59 Number of Products by Stage and Mechanism of Action, H1 2015 61 Number of Products by Stage and Route of Administration, H1 2015 63 Number of Products by Stage and Molecule Type, H1 2015 65 Pandemic Influenza Therapeutics - Recent Pipeline Updates, H1 2015 118 Pandemic Influenza - Dormant Projects, H1 2015 127 Pandemic Influenza - Dormant Projects (Contd..1), H1 2015 128 Pandemic Influenza - Discontinued Products, H1 2015 129
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
